FAQ – Your questions, answered.
Answers to common inquiries about products from Rapids Health.
Browse by Category
Ori
Ori by Rapids Health is an AI-powered clinical decision support tool that makes evidence-based and expert-informed psychiatric knowledge available to clinicians.
Keeping up-to-date with evolving psychiatric knowledge can be difficult. It takes time to sift through resources, and specialist consults can be hard to get. Ori delivers trusted, evidence-based and expert-informed guidance instantly, so you can more effectively help your patients – without the wait.
At this time, you can ask questions about psychiatric medications and decision support related to pharmacotherapy, as well as questions related to clinical presentations to generate structured treatment guidance for MDD and GAD. New disorders will be added soon.
Ori provides guidance related to major depressive disorder (MDD) and generalized anxiety disorder (GAD). Guidance related to insomnia, ADHD, and bipolar disorder will be added in the coming months.
The Rapids knowledge base is a curated repository of clinical information on psychiatric medications and comprehensive treatment guidance sourced from published guidelines, peer-reviewed research, and clinical expertise. The knowledge has been selected by leaders in the field of psychiatry and psychopharmacology and logic-driven treatment guidance has been validated by a panel of psychiatric experts.
Ori is an AI-powered clinical decision support tool that makes evidence-based and expert-informed psychiatric knowledge accessible instantly, safely, and in context, to support confident and informed clinical decision-making. Soli (known to many as RAPIDS) is a clinical decision support service that automates patient assessments and provides evidence-based treatment and diagnostic guidance, in a report, personalized for each patient.
Information about Ori is updated regularly; go here to test Ori or join our beta waitlist.
Soli (Rapids)
Soli is the new name for Rapids, our clinical decision support service that provides personalized diagnostic and treatment guidance in a detailed report to support clinical decision-making.
Using clinical scales is standard psychiatric care. Soli automates scale delivery, streamlines the collection of patient information to support a DSM-5-TR diagnosis, and automates follow-up monitoring. Evidence-based, clinically informed guidance reduces administrative burden, accelerates treatment decisions, and provides patient education to support engagement, shared decision-making, and adherence.
Patients aged 18-65 with symptoms of mood disorders (MDD and bipolar), anxiety, insomnia and/or ADHD can benefit from Soli.
Soli subscribers have access to Soli smart forms for the following EMRs: Accuro, CHR, Juno, MedAccess, Medesync, MOIS, Myle, PS Suite, Oscar, Plexia and Profile.
Soli (the product you know as RAPIDS) will continue to run exactly as it always has. We have updated the name and brand to bring it in line with our new solution, Ori, that is now available for testing. We’ve launched a new website, and we now offer online access to customer support and resources. Summary of changes:
- the product is now called Soli
- we have updated our brand (you may have noticed, the website looks quite different!)
- you can contact us now through our new service desk (i.e. not via email)
- the Terms and Conditions have been updated.
You should receive communications from Rapids in your email about these changes and the updated Terms of Use. If you have not, please contact us.
Soli (known to many as Rapids) is a clinical decision support service that automates patient assessments and provides evidence-based treatment and diagnostic guidance, in a report, which is personalized for each patient. Ori is a new AI-powered clinical decision support tool that makes evidence-based and expert-informed psychiatric knowledge accessible instantly, safely, and in context, to support confident and informed clinical decision-making.
Yes, Rapids – now Soli – is available. See here to subscribe.
Early access
We’re inviting eligible users to join our alpha program and join the waitlist for early access to Ori when beta is released this spring. Learn more
We are recruiting for eligible users to join the alpha test group for Ori now. Currently eligible are Canadian family physicians and nurse practitioners. Ori will be available in beta to a broader group of Canadian prescribers starting Spring 2026; please join the waitlist to be first in line – no cost involved.
There is no cost for Ori or Soli at this time.
Not ready to join the alpha and beta programs? Want to keep up with exciting product updates? Join our mailing list and we’ll keep you updated.
